Medipharm Labs Corp - Asset Resilience Ratio

Latest as of December 2025: 23.63%

Medipharm Labs Corp (LABS) has an Asset Resilience Ratio of 23.63% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check LABS capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CA$10.81 Million

≈ $7.82 Million USD Cash + Short-term Investments

Total Assets

CA$45.74 Million

≈ $33.09 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2018–2025)

This chart shows how Medipharm Labs Corp's Asset Resilience Ratio has changed over time. See LABS net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Medipharm Labs Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Medipharm Labs Corp.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CA$10.81 Million	23.63%
Short-term Investments	CA$0.00	0%
Total Liquid Assets	CA$10.81 Million	23.63%

Asset Resilience Insights

Good Liquidity Position: Medipharm Labs Corp maintains a healthy 23.63% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Medipharm Labs Corp Industry Peers by Asset Resilience Ratio

Compare Medipharm Labs Corp's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Aurobindo Pharma Limited NSE:AUROPHARMA	Drug Manufacturers - Specialty & Generic	1.28%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	11.60%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Tianjin Chase Sun Pharmaceutical Co Ltd SHE:300026	Drug Manufacturers - Specialty & Generic	-0.89%
Zhejiang Hisoar Pharmaceutical Co Ltd SHE:002099	Drug Manufacturers - Specialty & Generic	0.20%
Xeris Pharmaceuticals Inc NASDAQ:XERS	Drug Manufacturers - Specialty & Generic	0.00%
Procter & Gamble Health Limited NSE:PGHL	Drug Manufacturers - Specialty & Generic	33.01%

Annual Asset Resilience Ratio for Medipharm Labs Corp (2018–2025)

The table below shows the annual Asset Resilience Ratio data for Medipharm Labs Corp.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	23.63%	CA$10.81 Million ≈ $7.82 Million	CA$45.74 Million ≈ $33.09 Million	+1.87pp
2024-12-31	21.76%	CA$11.69 Million ≈ $8.46 Million	CA$53.73 Million ≈ $38.87 Million	-6.78pp
2023-12-31	28.54%	CA$18.25 Million ≈ $13.20 Million	CA$63.94 Million ≈ $46.25 Million	-9.48pp
2022-12-31	38.02%	CA$24.90 Million ≈ $18.01 Million	CA$65.50 Million ≈ $47.38 Million	-0.15pp
2021-12-31	38.17%	CA$35.25 Million ≈ $25.50 Million	CA$92.36 Million ≈ $66.81 Million	+19.59pp
2020-12-31	18.58%	CA$21.97 Million ≈ $15.89 Million	CA$118.23 Million ≈ $85.53 Million	-4.70pp
2019-12-31	23.28%	CA$39.31 Million ≈ $28.43 Million	CA$168.83 Million ≈ $122.13 Million	+4.44pp
2018-12-31	18.84%	CA$8.05 Million ≈ $5.82 Million	CA$42.73 Million ≈ $30.91 Million	--

pp = percentage points

About Medipharm Labs Corp

TO:LABS Canada Drug Manufacturers - Specialty & Generic

Market Cap

$23.05 Million

CA$31.86 Million CAD

Market Cap Rank

#24670 Global

#951 in Canada

Share Price

CA$0.08

Change (1 day)

+7.14%

52-Week Range

CA$0.06 - CA$0.09

All Time High

CA$7.17